Therefore, it seems to us that ACE2 could be considered as a potential biomarker of inflammatory lung diseases or even a standard component in the medical treatment of COPD, asthma or pulmonary hypertension. This evidence concerns the gene ACE2 and pulmonary arterial hypertension.